Generali Asset Management SPA SGR Increases Holdings in Qiagen N.V. $QGEN

Generali Asset Management SPA SGR lifted its stake in shares of Qiagen N.V. (NYSE:QGEN) by 102.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 68,880 shares of the company’s stock after purchasing an additional 34,912 shares during the quarter. Generali Asset Management SPA SGR’s holdings in Qiagen were worth $3,078,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in QGEN. MAI Capital Management grew its holdings in Qiagen by 998.9% during the 2nd quarter. MAI Capital Management now owns 978 shares of the company’s stock valued at $47,000 after buying an additional 889 shares in the last quarter. Farther Finance Advisors LLC grew its stake in Qiagen by 400.5% during the second quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock valued at $51,000 after acquiring an additional 849 shares in the last quarter. Allworth Financial LP grew its stake in Qiagen by 260.1% during the second quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock valued at $53,000 after acquiring an additional 796 shares in the last quarter. Cullen Frost Bankers Inc. increased its holdings in Qiagen by 13,144.4% during the 2nd quarter. Cullen Frost Bankers Inc. now owns 1,192 shares of the company’s stock worth $57,000 after acquiring an additional 1,183 shares during the period. Finally, GAMMA Investing LLC lifted its stake in Qiagen by 375.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,241 shares of the company’s stock worth $55,000 after purchasing an additional 980 shares in the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Trading Up 0.4%

NYSE QGEN opened at $45.15 on Friday. The company has a quick ratio of 2.30, a current ratio of 2.60 and a debt-to-equity ratio of 0.45. The stock’s 50-day simple moving average is $45.73 and its two-hundred day simple moving average is $47.04. Qiagen N.V. has a twelve month low of $37.63 and a twelve month high of $51.88. The company has a market capitalization of $10.04 billion, a price-to-earnings ratio of 24.54, a PEG ratio of 2.19 and a beta of 0.66.

Qiagen’s stock is set to reverse split on the morning of Thursday, January 8th. The 19-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, January 7th.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.03. The company had revenue of $532.58 million for the quarter, compared to analysts’ expectations of $525.68 million. Qiagen had a return on equity of 14.80% and a net margin of 19.58%.Qiagen’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period last year, the firm posted $0.57 EPS. Research analysts forecast that Qiagen N.V. will post 2.26 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Qiagen in a research report on Monday, December 29th. Citigroup lowered Qiagen from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $55.00 to $50.00 in a research note on Thursday, December 11th. Barclays reiterated an “overweight” rating and set a $55.00 price target (up previously from $53.00) on shares of Qiagen in a research report on Monday, December 15th. Finally, Wall Street Zen raised Qiagen from a “hold” rating to a “buy” rating in a report on Sunday, December 21st. Two analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $49.61.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.